Welcome to our dedicated page for Arvinas news (Ticker: ARVN), a resource for investors and traders seeking the latest updates and insights on Arvinas stock.
Arvinas, Inc. develops targeted protein degradation medicines through its PROTAC protein degrader platform. Company updates center on VEPPANU (vepdegestrant), developed with Pfizer and approved by the FDA for adults with ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer after endocrine-based therapy, as well as regulatory, clinical, and corporate milestones tied to that program.
Arvinas news also covers investigational PROTAC degraders across oncology, neurology, and neuromuscular disease, including ARV-102 for LRRK2-driven neurodegenerative disorders, ARV-806 for KRAS G12D-mutated cancers, ARV-393 for BCL6-driven lymphoma, and ARV-027 as a polyQ-AR degrader. Recurring items include clinical data presentations, financial results, corporate updates, investor conferences, and governance changes.
Arvinas announced the acceptance of two abstracts for presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Congress. The event will be held from May 31 to June 4, 2024, in Chicago. The first abstract features initial results from a Phase 1/2 study of ARV-766, a PROTAC androgen receptor degrader, in metastatic castration-resistant prostate cancer. It will be presented on June 3, 2024, from 1:15 p.m. to 2:45 p.m. CDT under the Genitourinary Cancer category.
The second abstract involves TACTIVE-K, a Phase 1b/2 study of vepdegestrant, a PROTAC estrogen receptor degrader, in combination with Pfizer's investigational CDK4 inhibitor, PF-07220060, in ER+/HER2- advanced breast cancer. This will be presented on June 2, 2024, from 9:00 a.m. to 12:00 p.m. CDT in the Breast Cancer—Metastatic category. Abstracts can be accessed on the official ASCO website.
Arvinas and Pfizer announced updated data from a Phase 1b trial evaluating vepdegestrant in combination with palbociclib (IBRANCE®). After six months of additional follow-up, the clinical benefit rate (63%), overall response rate (41.9%), and median progression-free survival (11.2 months) remained consistent with prior results. At the recommended Phase 3 dose of 200 mg, median progression-free survival reached 13.9 months. Significant reductions in circulating tumor DNA were observed, regardless of ESR1 gene mutation status. The safety profile was consistent with previous findings, with Grade 3/4 neutropenia (91%) being the most common adverse event. These results were presented at the 2024 ESMO Breast Cancer Annual Congress.
Arvinas, Inc. (ARVN) to present two posters with updated clinical trial data for vepdegestrant at the 2024 ESMO Breast Cancer Annual Congress in Berlin, Germany. Vepdegestrant is a novel investigational drug for ER+/HER2- breast cancer jointly developed with Pfizer. The presentations are scheduled for May 16, 2024, showcasing promising results.
Arvinas reported strong Q1 2024 financial results along with key corporate updates. The company continued enrollment in multiple clinical studies of vepdegestrant in metastatic breast cancer, progressed ARV-102 for neurodegenerative diseases, and entered a lucrative transaction with Novartis. The strategic deal includes an exclusive license for ARV-766 and sale of the preclinical AR-V7 program, with significant upfront payment and potential milestone payments. Arvinas also made key appointments in its management team and remains on track with its Phase 3 clinical programs. Financially, the company's cash position is strong, with enough funding to support planned operations until 2027.
Arvinas, Inc. (Nasdaq: ARVN) will be presenting at two investor conferences: the BofA Securities 2024 Healthcare Conference on May 14 and the UBS Spring Biotech Conferences on May 21. The company's Chief Medical Officer and Chief Business Officer will participate in various discussions and meetings.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.